Schonfeld Strategic Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-640	Closed	-$12.8K	–	2833
2022 Q4	$12.8K	Sell	640 -375	-37%	-$7.46K	﹤0.01%	2346
2022 Q3	$18K	Hold	1,015	–	–	﹤0.01%	2718
2022 Q2	$23K	Sell	1,015 -10	-1%	-$223	﹤0.01%	2290
2022 Q1	$28K	Buy	+1,025	New	+$37.3K	﹤0.01%	2378
2021 Q3	–	Sell	-813	Closed	-$77K	–	2569
2021 Q2	$77K	Sell	813 -4,247	-84%	-$504K	﹤0.01%	1852
2021 Q1	$842K	Buy	5,060 +1,520	+43%	+$201K	0.01%	958
2020 Q4	$347K	Buy	+3,540	New	+$224K	﹤0.01%	1157

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Schonfeld Strategic Advisors's ONCT Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2023, closing a stake of 640 shares — an estimated $12.8K sold.

Schonfeld Strategic Advisors first reported a position in ONCT in Q4 2020 and held it in 7 quarters. The position peaked at $842K in Q1 2021. 54 funds tracked by Wall St. Rank hold ONCT as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 640 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $12.8K.
Schonfeld Strategic Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Schonfeld Strategic Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $842K in Q1 2021.
54 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.